Literature DB >> 25407607

Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.

Sharon M Moe1, Neal X Chen, Christopher L Newman, Jason M Organ, Michaela Kneissel, Ina Kramer, Vincent H Gattone, Matthew R Allen.   

Abstract

Chronic kidney disease (CKD) is associated with abnormalities in bone quantity and quality, leading to increased fractures. Recent studies suggest abnormalities of Wnt signaling in animal models of CKD and elevated sclerostin levels in patients with CKD. The goal of this study was to evaluate the effectiveness of anti-sclerostin antibody treatment in an animal model of progressive CKD with low and high parathyroid hormone (PTH) levels. Cy/+ male rats (CKD) were treated without or with calcium in the drinking water at 25 weeks of age to stratify the animals into high PTH and low PTH groups, respectively, by 30 weeks. Animals were then treated with anti-sclerostin antibody at 100 mg/kg i.v. weekly for 5 doses, a single 20-µg/kg subcutaneous dose of zoledronic acid, or no treatment, and were then euthanized at 35 weeks. As a positive control, the efficacy of anti-sclerostin antibody treatment was also evaluated in normal littermates. The results demonstrated that the CKD animals with high PTH had lower calcium, higher phosphorus, and lower FGF23 compared to the CKD animals with low PTH. Treatment with anti-sclerostin antibody had no effect on any of the biochemistries, whereas zoledronic acid lowered dkk-1 levels. The anti-sclerostin antibody increased trabecular bone volume/total volume (BV/TV) and trabecular mineralization surface in animals with low PTH, but not in animals with high PTH. Neither anti-sclerostin antibody nor zoledronic acid improved biomechanical properties in the animals. Cortical porosity was severe in high-PTH animals and was unaffected by either treatment. In contrast, in normal animals treated with anti-sclerostin antibody, there was an improvement in bone volume, cortical geometry, and biomechanical properties. In summary, this is the first study to test the efficacy of anti-sclerostin antibody treatment on animals with advanced CKD. We found efficacy in improving bone properties only when the PTH levels were low.
© 2014 American Society for Bone and Mineral Research.

Entities:  

Keywords:  CKD-MBD; FGF23; PARATHYROID HORMONE; RENAL OSTEODYSTROPHY; SCLEROSTIN; WNT

Mesh:

Substances:

Year:  2015        PMID: 25407607      PMCID: PMC4333005          DOI: 10.1002/jbmr.2372

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  47 in total

1.  Effects of denosumab on fracture and bone mineral density by level of kidney function.

Authors:  Sophie A Jamal; Osten Ljunggren; Catherine Stehman-Breen; Steven Ron Cummings; Michael R McClung; Stefan Goemaere; Peter R Ebeling; Edward Franek; Yu-Ching Yang; Ogo I Egbuna; Steven Boonen; Paul D Miller
Journal:  J Bone Miner Res       Date:  2011-08       Impact factor: 6.741

2.  A rat model of chronic kidney disease-mineral bone disorder.

Authors:  Sharon M Moe; Neal X Chen; Mark F Seifert; Rachel M Sinders; Dana Duan; Xianming Chen; Yun Liang; J Scott Radcliff; Kenneth E White; Vincent H Gattone
Journal:  Kidney Int       Date:  2008-09-17       Impact factor: 10.612

3.  Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients.

Authors:  Daniel Cejka; Agnes Jäger-Lansky; Heidi Kieweg; Michael Weber; Christian Bieglmayer; Dominik G Haider; Danielle Diarra; Janina M Patsch; Franz Kainberger; Barbara Bohle; Martin Haas
Journal:  Nephrol Dial Transplant       Date:  2011-05-25       Impact factor: 5.992

4.  Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls.

Authors:  A H van Lierop; J E Witteveen; N A T Hamdy; S E Papapoulos
Journal:  Eur J Endocrinol       Date:  2010-09-03       Impact factor: 6.664

5.  The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.

Authors:  Sharon M Moe; J Scott Radcliffe; Kenneth E White; Vincent H Gattone; Mark F Seifert; Xianming Chen; Blaire Aldridge; Neal X Chen
Journal:  J Bone Miner Res       Date:  2011-11       Impact factor: 6.741

6.  Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy.

Authors:  Yves Sabbagh; Fabiana Giorgeti Graciolli; Stephen O'Brien; Wen Tang; Luciene Machado dos Reis; Susan Ryan; Lucy Phillips; Joseph Boulanger; Wenping Song; Christina Bracken; Shiguang Liu; Steven Ledbetter; Paul Dechow; Maria Eugenia F Canziani; Aluizio B Carvalho; Vanda Jorgetti; Rosa M A Moyses; Susan C Schiavi
Journal:  J Bone Miner Res       Date:  2012-08       Impact factor: 6.741

Review 7.  WNT signaling in bone homeostasis and disease: from human mutations to treatments.

Authors:  Roland Baron; Michaela Kneissel
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

8.  Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo.

Authors:  Yumie Rhee; Nicoletta Bivi; Emily Farrow; Virginia Lezcano; Lilian I Plotkin; Kenneth E White; Teresita Bellido
Journal:  Bone       Date:  2011-06-25       Impact factor: 4.398

9.  Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms.

Authors:  Robert L Jilka; Charles A O'Brien; Shoshana M Bartell; Robert S Weinstein; Stavros C Manolagas
Journal:  J Bone Miner Res       Date:  2010-11       Impact factor: 6.741

10.  Control of bone mass and remodeling by PTH receptor signaling in osteocytes.

Authors:  Charles A O'Brien; Lilian I Plotkin; Carlo Galli; Joseph J Goellner; Arancha R Gortazar; Matthew R Allen; Alexander G Robling; Mary Bouxsein; Ernestina Schipani; Charles H Turner; Robert L Jilka; Robert S Weinstein; Stavros C Manolagas; Teresita Bellido
Journal:  PLoS One       Date:  2008-08-13       Impact factor: 3.240

View more
  49 in total

Review 1.  Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease.

Authors:  Ziad Massy; Tilman Drueke
Journal:  J Nephrol       Date:  2017-04-12       Impact factor: 3.902

2.  Sclerostin is essential for alveolar bone loss in occlusal hypofunction.

Authors:  Yang Xu; Lufei Wang; Yao Sun; Xianglong Han; Tian Gao; Xin Xu; Tian Chen; Xuefeng Zhao; Huan Zeng; Yanmin Wang; Ding Bai
Journal:  Exp Ther Med       Date:  2016-03-02       Impact factor: 2.447

3.  Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing.

Authors:  Elizabeth A Swallow; Mohammad W Aref; Corinne E Metzger; Spencer Sacks; Demi R Lehmkuhler; Neal Chen; Max A Hammond; Paul R Territo; Thomas L Nickolas; Sharon M Moe; Matthew R Allen
Journal:  Bone       Date:  2019-07-09       Impact factor: 4.398

4.  Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney disease.

Authors:  E A Swallow; M W Aref; N Chen; I Byiringiro; M A Hammond; B P McCarthy; P R Territo; M M Kamocka; S Winfree; K W Dunn; S M Moe; M R Allen
Journal:  Osteoporos Int       Date:  2018-06-11       Impact factor: 4.507

Review 5.  Role and mechanism of action of sclerostin in bone.

Authors:  Jesus Delgado-Calle; Amy Y Sato; Teresita Bellido
Journal:  Bone       Date:  2016-10-12       Impact factor: 4.398

6.  Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease.

Authors:  Toshifumi Sugatani; Olga A Agapova; Yifu Fang; Alycia G Berman; Joseph M Wallace; Hartmut H Malluche; Marie-Claude Faugere; William Smith; Victoria Sung; Keith A Hruska
Journal:  Kidney Int       Date:  2016-09-22       Impact factor: 10.612

7.  Time course of rapid bone loss and cortical porosity formation observed by longitudinal μCT in a rat model of CKD.

Authors:  Erin M B McNerny; Dorothy T Buening; Mohammad W Aref; Neal X Chen; Sharon M Moe; Matthew R Allen
Journal:  Bone       Date:  2019-05-03       Impact factor: 4.398

Review 8.  Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.

Authors:  Jordi Bover; Lucía Bailone; Víctor López-Báez; Silvia Benito; Paola Ciceri; Andrea Galassi; Mario Cozzolino
Journal:  J Nephrol       Date:  2017-04-21       Impact factor: 3.902

9.  Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients?

Authors:  S Pelletier; C B Confavreux; J Haesebaert; F Guebre-Egziabher; J Bacchetta; M-C Carlier; L Chardon; M Laville; R Chapurlat; G M London; M-H Lafage-Proust; D Fouque
Journal:  Osteoporos Int       Date:  2015-04-25       Impact factor: 4.507

10.  Only minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease.

Authors:  Daniel Cejka; Diego Parada-Rodriguez; Stefanie Pichler; Rodrig Marculescu; Ina Kramer; Michaela Kneissel; Thomas Gross; Andreas Reisinger; Dieter Pahr; Marie-Claude Monier-Faugere; Martin Haas; Hartmut H Malluche
Journal:  Kidney Int       Date:  2016-08-12       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.